Welcome to SureStone Capital, formerly Ausbiz CapitalSame team, same ABN and AFS authorisations. Our name changed on 1 October 2026.
All Neuren Pharmaceuticals Limited (ASX:NEU) announcement summaries, newest first. Every summary is drawn only from the company's official ASX release.
Neuren said the European Commission approved DAYBU (trofinetide) for neurobehavioral symptoms of Rett syndrome, a first in the EU. Acadia is Neuren's licensee.
25 Aug, 2026
Neuren reported partner Acadia's Q2 2026 DAYBUE net sales of US$125m, up 30%, and said its own full-year 2026 royalty income is now expected at US$53-56m.
05 Aug, 2026
